Results 11 to 20 of about 22,516 (228)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment

Biomedicines, 2021
Recent advances in prostate cancer (PC) research unveiled real androgen receptor (AR) functions in castration-resistant PC (CRPC). Moreover, AR still accelerates PC cell proliferation via the activation of several mechanisms (e.g., mutation, variants ...
Tomoyuki Makino, Kouji Izumi, Atsushi Mizokami   +2 more
doaj   +2 more sources

The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing

Frontiers in Cell and Developmental Biology, 2021
Castration-resistant prostate cancer (CRPC) is the major cause of death from prostate cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-invasive liquid biopsies could improve outcomes.
Tianyu Guo, Tianyu Guo, Yang Wang, Yang Wang, Jing Jia, Xueying Mao, Elzbieta Stankiewicz, Glenda Scandura, Edwina Burke, Lei Xu, Lei Xu, Jacek Marzec, Jacek Marzec, Caitlin R. Davies, Jiaying Jasmin Lu, Prabhakar Rajan, Prabhakar Rajan, Prabhakar Rajan, Prabhakar Rajan, Alistair Grey, Alistair Grey, Karen Tipples, John Hines, John Hines, Sakunthala Kudahetti, Tim Oliver, Thomas Powles, Constantine Alifrangis, Constantine Alifrangis, Manish Kohli, Manish Kohli, Greg Shaw, Greg Shaw, Greg Shaw, Wen Wang, Ninghan Feng, Jonathan Shamash, Daniel Berney, Liang Wang, Yong-Jie Lu, Yong-Jie Lu   +40 more
doaj   +1 more source

Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC

, 2021
Background: Metastatic castration-resistant prostate cancer (CRPC) is the leading cause of death among prostate cancer patients. Here, our aim was to ascertain the immune regulatory mechanisms involved in CRPC development and identify potential ...
Min Li, Fanlin Li, Xinyue Qi, Jingjing Cao, Lilv Fan, Guiliang Xu, Ping Han, Huihui Zhang, Xiaoqing Zhang, Zeyu Li, Xuanming Yang   +10 more
core   +1 more source

The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer

Molecular & Cellular Oncology, 2020
Alternative splicing (AS) analysis across the entire spectrum of human prostate cancer evolution reveals the unexpected findings that intron retention is a hallmark of stemness and tumor aggressiveness, and androgen receptor controls a splicing program ...
Cheng Zou, Dingxiao Zhang
doaj   +1 more source

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib

Journal of Immunology Research, 2022
This project attempts to clarify the expression of MUS81 in castration-resistant prostate cancer (CRPC) and the effect on drug sensitivity to Olaparib.
Lifeng Gong, Yu Tang, Li Jiang, Wei Tang, Shengjun Luo   +4 more
doaj   +1 more source

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone

Frontiers in Pharmacology, 2016
Background: A systemic immune-inflammation index (SII) based on neutrophil (N), lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid tumors.
Cristian Lolli, Orazio Caffo, Emanuela Scarpi, Michele Aieta, Vincenza Conteduca, Francesca Maines, Emanuela Bianchi, Francesco Massari, Antonello Veccia, Vincenzo E. Chiuri, Gaetano Facchini, Ugo De Giorgi   +11 more
doaj   +1 more source

Mechanisms of resistance in castration-resistant prostate cancer (CRPC) [PDF]

, 2015
Despite advances in prostate cancer diagnosis and management, morbidity from prostate cancer remains high. Approximately 20% of men present with advanced or metastatic disease, while 29,000 men continue to die of prostate cancer each year.
Chandrasekar, Thenappan, Yang, Joy C, Gao, Allen C, Evans, Christopher P   +3 more
core   +1 more source

Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway

Frontiers in Oncology, 2020
Castration-resistant prostate cancer (CRPC) is a progressed stage of prostate cancer, which requires better understanding of the mechanisms and remains an unmet clinical need. As a common oncogene, K-Ras is associated with malignant behavior in different
Jiayu Liu, Yongbo Zheng, Yingying Gao, Yingying Gao, Zhen Quan, Bo Qiao, Luo Li, Luo Li, Ting Li, Limei Duan, Jinxiao Yang, Chunli Luo, Xiaohou Wu   +12 more
doaj   +1 more source

Baseline characteristics of 124 CRPC patients after PSM.

, 2021
Baseline characteristics of 124 CRPC patients after PSM.
Jun Miki (11512692), Shin Egawa (10695845), Shotaro Nakanishi (11512689), Takuma Oshiro (10919581), Takahiro Kimura (2344582), Seiichi Saito (10919584), Mitsuyoshi Tamaki (10919578), Tatsuya Shimomura (11512695), Hiroki Yamada (5435), Shunsuke Tsuzuki (11512686), Nozomu Furuta (11512698)   +10 more
core   +1 more source

Immunotherapy for prostate cancer: Lessons from responses to tumor-associated antigens

Frontiers in Immunology, 2014
Prostate cancer is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for prostate cancer have been developed and studied extensively in clinical trials.
Harm eWestdorp, Harm eWestdorp, Annette E. Skold, Berit A. Snijer, Sebastian eFranik, Sasja F. Mulder, Pierre Paul Major, Ronan eFoley, Winald R. Gerritsen, I. Jolanda M. de Vries, I. Jolanda M. de Vries   +10 more
doaj   +1 more source